Když se řekne infekce

MUDr. Hana Roháčová, Ph.D

Interní Med. 2016; 18(3)  

Current view of the pharmacotherapy of COPD

doc. MUDr. Norbert Pauk, Ph.D.

Interní Med. 2016; 18(3): 114-119 | DOI: 10.36290/int.2016.028  

In Europe, the prevalence ranges from 4 % to 10 % in persons over 40 yearsof age. However, the condition is largely underdiagnosed and the number of patients is expected to be two-fold and the prevalence hasbeen steadily increasing, particularly among women. Modern pharmacotherapy can affect numerous parameters, improves the quality of life of patients, alleviates the symptoms, reduces exacerbations and appears to positively affect the disease-related mortality.

News in the treatment of bronchial asthma in adults

MUDr. Lucie Heribanová

Interní Med. 2016; 18(3): 120-123 | DOI: 10.36290/int.2016.029  

This article informs about new possibilities in the treatment of severe refractory asthma, including the possibility of using tiotropium, macrolides and biological treatment for asthma.

Antidiabetic drugs of interest

prof.MUDr.Milan Kvapil, CSc.

Interní Med. 2016; 18(3): 125-129 | DOI: 10.36290/int.2016.036  

The increasing prevalence of type 2 diabetes mellitus is a major epidemiological, clinical, and economic issue. Good-quality treatment aimed at achieving normal blood sugar levels is essential in order to prevent complications. Novel molecules (dapagliflozin, empagliflozin, imeglimin, liraglutide, omarigliptin, ranolazine, and sitagliptin) that have been introduced in the clinical practice in the recent years, or are going to be introduced, show a lower risk of hypoglycaemia, thus allowing superior prevention of late complications of type 2 diabetes.

Recommendations for care of patients with diabetes and kidney impairment

MUDr. Jan Vachek, MUDr. PhDr. Oskar Zakiyanov, Ph.D., prof. MUDr. Vladimír Tesař, DrSc., MBA, FASN, FERA

Interní Med. 2016; 18(3): 130-133 | DOI: 10.36290/int.2016.030  

The attending physician treating a patient with diabetes is frequently confronted with the simultaneous presence of both diseases: diabetes and reduced kidney function. Patients with diabetes are at high risk of developing kidney disease in comparison with general population, and timely evaluation for the decline of renal function in these patients is very important. Many metabolic changes namely the enhanced catabolism at progressive loss of renal function, diminished gluconeogenesis and glycogenolysis, pharmacokinetic changes of medicaments including antidiabetics should be taken into account at the decrease of glomerular filtration rate...

Current problems of primary hyperparathyroidism in clinical practice

MUDr.Helena Šiprová, prof.MUDr.Miroslav Souček, CSc., prof.MUDr.Květoslav Šipr, CSc.

Interní Med. 2016; 18(3): 134-136 | DOI: 10.36290/int.2016.031  

Primary hyperparathyroidism (PHPT) is the third most often endocrine disease worldwide and the number of cases is growing up due to a frequent use of biochemical screening. Particularly number of asymptomatic and normocalcemic PHPT increases and therapy results have improved significantly. It is necessary to treat also the asymptomatic patients, and in such a way reduce the risk of major complications.

Hyperuricaemia and gouty arthropathy: diagnosis and treatment

MUDr.Radka Svobodová

Interní Med. 2016; 18(3): 137-141 | DOI: 10.36290/int.2016.032  

Hyperuricaemia refers to a pathological increase in serum uric acid level. Long-lasting hyperuricaemia can lead to so-called gouty arthropathy that is manifested by a response of the body to uric acid (sodium urate) crystal deposition in joints as well as soft tissues. Hyperuricaemia can initially be asymptomatic; later on, it can present as acute gouty arthritis. When during sodium urate crystal deposition in tissues and articular structures their destruction occurs, this is referred to as chronic arthropathic tophaceous gout; when there is sodium urate deposition in the kidneys, it is called urate nephropathy. The diagnosis of gout is based...

Successful ultrasound-guided percutaneous ethanol ablation of an parathyroid adenoma of ninety-year-old senior

MUDr. Milan Halenka, Ph.D., doc. MUDr. Zdeněk Fryšák, CSc., doc. MUDr. David Karásek, Ph.D., doc. MUDr. Pavel Koranda, Ph.D., MUDr.Iva Metelková, Ph.D.

Interní Med. 2016; 18(3): 146-149 | DOI: 10.36290/int.2016.034  

Percutaneous Ethanol Injection Therapy of parathyroid adenoma under ultrasound guidance is individually used as an alternative procedure in management of primary hyperparathyroidism in polymorbid elderly patients with increased surgical risk. We present a case of a 92-year-old male patient, who underwent thyroidectomy for papillary thyroid carcinoma three years ago. Part of the regular annual follow-up visits was also ultrasonography, which showed a solitary parathyroid adenoma at the site of the removed thyroid gland. Given the underlying condition, polymorbidity and age of the patient, the PEIT method was successfully used in the therapy....

Patient with metastatic process in the skeleton of unknown etiology

MUDr.Mária Majerníková, MUDr.Jan Sedláček, MUDr.Zdeněk Monhart, Ph.D.

Interní Med. 2016; 18(3): 150-154 | DOI: 10.36290/int.2016.035  

Bearing bone involvement is a possible sign of generalization variety of cancers. In many cases the process of bearing skeletal diagnosed at the time when the primary tumor is not obvious. The task of the physician is quickly to determine whether it is a benign process or not, and diagnosis of the primary process by which then determine the further progress of therapy. The search for causative bearing shell process, alternatively the primary tumor, is often common practice in the hands of internist. Departments of Clinical Oncology do not have to have sufficient capacity for complex treatment all of newly discovered deposits skeleton whose...

Zaznělo na kongresu American Diabetes Association

MUDr. Marek Honka

Interní Med. 2016; 18(3): 142-145